IFF and BASF Pharma Solutions have joined forces to onboard IFF’s leading product brands in pharmaceutical excipients on BASF’s Virtual Pharma Assistant platform—ZoomLab. The platform is a science-based digital tool designed to predict the best excipients needed for the development of new pharmaceutical formulations to help overcome formulation challenges.
 
BASF’s proprietary algorithm, ZoomLab, allows formulators to accelerate formulation design by predicting the most effective excipients to match a given active pharmaceutical ingredient (API). It also allows them to make customizations, offering a range of ingredients to choose from, including IFF’s excipients.
 
In the first phase of the collaboration, IFF’s product line Avicel microcrystalline cellulose (MCC) and super disintegrant Ac-Di-Sol croscarmellose sodium will be available to users in the ZoomLab excipient database and throughout the various ZoomLab modules.
 
“Our collaboration with IFF aligns well with our commitment to provide exceptional value to our customers through our digital Virtual Pharma Assistants,” said Jeffrey DeAlmeida, senior vice president, BASF Pharma Solutions and Nutrition and Health, Americas. “Including IFF products within ZoomLab underlines our ambition to continuously develop ZoomLab into the leading industry platform giving users access to a broad range of excipients and make it even easier to create formulations quickly. We will continue to deepen our collaboration on ZoomLab in the future including more content and features for users.”
 
Angela Strzelecki, president, IFF Pharma Solutions, said, “At IFF, we apply a customer-centric approach to problem-solving throughout the drug development process. We are committed to being the partner our customers can count on, and now, thanks to our exciting collaboration with BASF on ZoomLab, we are helping even more customers innovate and overcome their formulation challenges. The addition of our renowned ingredients into this platform enhances the ability of ZoomLab to predict the best formulations and accelerates the launch of more innovative products across the global pharmaceutical market which is good for manufacturers and patients around the world.”